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1 Introduction1 
1.1 An overview on current market state 
The Chinese pharmaceutical industry represents a perfect example of China’s impressive 
change over the last 30 years. 
After opening up its policy, China started to change very fast. Its economy became 
the second largest in the world, making China one of the most attractive markets and 
making Chinese society an incubator of new demands. 
Owing to years of family planning under the one-child policy, Chinese society can be 
nowadays defined as an ageing society, which means not only a greying population but 
also a new market of demands, especially in the healthcare sector. 
New disease diagnoses have increased2 and consequently both personal and total 
national healthcare expenditure has risen (see Figure 1). 
Aside from the dramatic meaning of these data, figures show the Chinese 
pharmaceutical industry has a strong growth potential. This has been confirmed by the 
12th Five-Year Plan through which the Chinese Government has launched new policies 
directed toward strengthening the industry, an evident confirmation that the Chinese 
Government glimpses a promising market. 
The current situation denotes that the Chinese healthcare sector is dominated by the 
pharmaceutical sub-sector and, even more important, also denotes that with a value 
estimation of US$83.3 billion (The Economist, 2014) (at the end of 2013) the Chinese 
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pharmaceutical market is expected to become greater than the parallel Japanese sector in 
next few years. 
Figure 1 China’s healthcare expenditure 2000–2014 
 
Source: China Statistical Yearbook 2015 
As briefly noted above, it can be said the fast and growing importance of the  
Chinese pharmaceutical sector in the economy is a result of a combination of  
macro-environmental and industry-driven factors. 
The ageing population issue and the increase of new diseases represent mere 
examples and must be considered alongside the rapid domestic economic growth, 
Chinese policies reforming the entire healthcare industry (including pharmaceuticals), as 
well as all the global and national structural changes in the pharmaceutical industry 
(consider, for example, the pharmerging3 markets phenomenon). 
From a theoretical point of view, recent statistics on sales market value and forecasted 
data of ‘what next?’ For the Chinese pharmaceutical sector (Pharmaceutical Industry in 
China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma 
Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, 
Opportunities & Challenges, 2015) are undoubtedly very attractive. However, the 
practical experiences of many big multinational companies seem to suggest the Chinese 
pharmaceutical industry is actually very complex.4 Therefore, success inevitably requires 
on one hand a deep knowledge of the market structure, and on the other hand a strong 
local presence. 
Planning a business in China’s pharmaceutical industry – which could mean playing 
in the manufacturing and/or distribution industry – could be extremely problematic due to 
a multi-layered structure chain and a fragmented and complex regulatory legal 
framework. 
1.2 A challenging legal framework 
It is unanimously recognised in the literature that although the Chinese pharmaceutical 
market offers huge opportunities to European industry, it poses several challenges 
regarding compliance with the laws governing this sector (Schatz, 2015). 
Owing to different legal traditions, a distinctive public health history and culture, and 
a completely different system of healthcare, European Union (EU) companies have faced 
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many barriers in accessing the Chinese pharmaceutical market over the years (European 
Commission, 2011). Foreign pharmaceutical firms operating in China have experienced 
many difficulties in the form of legal and regulatory hurdles, such as those stemming 
from the drug registration process – notoriously long and complicated compared to EU 
procedures – and from the drug distribution system, which is hampered by complex 
regulations. Other concerns regard intellectual property (IP) right issues, especially “the 
lack of proper data exclusivity protection, the absence of patent term restoration, 
counterfeiting, inconsistent administrative protection, and enforcement” [Griesar, (2006), 
p.23]. 
The existing legal framework on pharmaceutical products has been developed from 
the early 1980s, when the People’s Congress of China approved the Drug Administration 
Law.5 This Law, which still represents the basic legislation regulating the sector, marked 
a ‘new era’ for the administration of drugs in China, characterised by more attention to 
strengthening regulations and the safety and quality of pharmaceuticals.6 The Drug 
Administration Law has been enforced and implemented by several regulations aiming to 
“protect public health and promote economic development in the pharmaceutical sector 
by establishing a legislative process for the regulation of drug manufacturing, distribution 
and purchasing” [Yan et al., (2013), p.714]. Among these instruments, the Regulations 
for the implementation of the Drug Administration Law (hereinafter Regulations) is of 
primary importance.7 
The regulatory framework is completed by several technical guidance documents 
issued by the China Food and Drug Administration (CFDA), (formerly the State Food 
and Drug Administration and earlier the State Drug Administration), which is the 
ministerial-level authority (on the same level as the Ministry of Health) under the control 
of the State Council in charge of drafting, applying and enforcing drug regulation, as well 
as drug registration and other relevant functions concerning drugs (Tan et al., 2015). 
Moreover, it is necessary to take into consideration the special provisions reserved for 
foreign investors and the rules on IP rights, as explained hereafter. 
China is continuously improving its pharmaceutical regulation, aiming to align it with 
EU and the USA standards in order to guarantee the safety, quality and efficacy of drugs, 
to foster the development of the domestic pharmaceutical industry and to encourage 
foreign investment in conformity with the ‘opening-up’ policy. 
Against this background, this article aims to provide a better understanding of 
China’s drug regulatory framework and its emerging trends. For these purposes, it 
focuses on three critical legal topics, which are relevant to the business of EU 
pharmaceutical companies in the Chinese market: drug registration, drug distribution and 
IP rights protection. The paper is structured as follows: Paragraph 2 is focused on drug 
registration regulation. The evolution and the development of the distribution sector and 
the different investment channels and models to enter major segments of the Chinese 
market are described in Paragraph 3, while Paragraph 4 is about IP rights issues. 
2 The drug registration regulation 
EU companies can place their pharmaceutical products on the Chinese market only after 
having successfully completed a drug registration application with the CFDA. 
Unfortunately for them, “China currently has arguably the world’s most complex 
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requirements for the introduction of new drugs, second only, perhaps, to Japan” [Griesar, 
(2006), p.17]. Over the years, foreign companies have come up against many regulatory 
barriers, such as: requirements for the registration process that are unique for each drug 
and different from international guidelines; long CFDA review timelines for each step of 
the registration procedure compared to those of other countries; onerous clinical trial 
processes before the first step of registration, requiring the repetition of some clinical 
stage for pharmaceuticals and even the full development of vaccines; frequent and 
unexpected changes in registration procedures; limited dialogue with CFDA staff 
[Griesar, (2006), p.22; European Commission, 2011). One of the most critical elements 
of this complicated regulatory environment is the time required when a company decides 
to enter the Chinese market. Last year the CFDA reported a backlog of drug registration 
applications, which further hinders market entry.8 This situation is damaging not only to 
foreign companies, but also to Chinese patients who have to wait a long time to receive 
benefits from innovative drugs available abroad. 
The drug registration process is regulated by the Drug Administration Law and the 
Regulations for implementation of the Drug Administration Law, which set out the basic 
regulation for pharmaceutical registration. This basic regulation has been enhanced by the 
Provisions for Drug Registration (also known as Measures of the Administration of Drug 
Registration or Drug Regulation Registration, hereinafter Provisions),9 which detail the 
technical requirements and procedures for application, review and approval. Furthermore, 
the CFDA has issued several technical guidelines to support applicants at each step of the 
procedure. 
According to these registration rules, there are five types of registration applications 
(Provisions, article 11): 
1 new drugs applications 
2 generic drugs applications 
3 imported drug applications 
4 supplementary applications 
5 re-registration applications. 
While the fourth and fifth respectively concern applications to modify an already 
registered drug and applications for licence renewal, the other types focus on the first  
pre-market approval. The choice among them depends on the drug category and class that 
the pharmaceutical product to be registered belongs to. In fact, the Chinese registration 
system classifies pharmaceuticals into three categories:10 chemical drugs, biological 
drugs, and Traditional Chinese Medicine (TCM). Each category is subdivided into 
several classes (6 classes of chemical drugs, 15 classes of biological drugs and 9 classes 
of TCM). For each class the Provisions for Drug Registration provides the registration 
application and the documentation for research and clinical trials. 
In brief, a new drug application is needed for the registration of a pharmaceutical 
product that will be manufactured in China but not marketed in China yet (for example, 
class 1 for chemical drugs); a generic drug application is necessary for the registration of 
a pharmaceutical product to be manufactured in China but which is a generic version of 
the drug already approved by the CFDA according to national standards (for example, 
class 6 of chemical drugs); and an imported drug application is required for the 
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registration of a drug manufactured abroad and already approved abroad (for example, 
class 3 of chemical drugs). 
The registration process for the three applications is divided into several steps. The 
new drug and imported drug registration processes are pretty similar;11 their registration 
applications involve two approval procedures: approval for clinical trials and approval for 
new drug applications or for imported drug applications, and, accordingly, two 
applications – an application for clinical trials (CTA) and an application for new drugs 
(NDA) or for an imported drug licence (IDL) submitted upon completion of the clinical 
trials. Once issued, the New Drug Certificate (NDC) or the Imported Drug License (IDL) 
is valid for five years. 
The thorniest step of the process is that of clinical trials. Their requirements are 
specified according the drug classification and application type. Generally, local clinical 
trials are mandatory and can be carried out only at CFDA-accredited hospitals, after 
obtaining CTA approval. “Even if a product is approved elsewhere in the world, the 
SFDA is still likely to require the foreign manufacturer to conduct at least one study in 
China before approval. Results from overseas trials can only be regarded as referential 
clinical data” [Zhang, (2011), p.165]. 
For instance, in the case of new chemical drugs, subject to a new drug application, a 
drug developer (i.e., a clinical trial sponsor) must conduct a three-phase clinical 
evaluation program (including Phases I, II and III of the clinical trials). For new chemical 
drugs, subject to an imported drug application, only a Pharmokinetics study and 
abbreviated Phase III trial with 200 cases or an abbreviated Phase III trial with 100 cases 
for treatment arm only are requested. 
For overseas applicants, when a drug has already been registered abroad or submitted 
to Phase II or Phase III clinical trials in another country, the Provisions (art. 44) provide 
the opportunity to conduct an international multicentre clinical trial – also known as 
multi-regional clinical trials (MRCTs) – a clinical trial performed simultaneously in 
multiple regions or countries following an identical protocol.12 Upon completion of the 
MRCT, which must be conducted in conformity with the clinical trials requirements of 
the Provisions, the applicant shall submit the complete report to the CFDA, “and then this 
regulatory procedure is over automatically” [Zhang, (2011), p.165]. 
Finally, it is worth noting that Chinese registration rules (specifically, the Rules on 
Special Approval for New Drug, issued by the CFDA in 2009) also set forth a special 
registration procedure for new drugs that meet certain requirements (also known as Green 
Channel). Substantially, this special channel provides fast-track review and approval, 
offering a shorter approval process and a preferential communication channel between 
applicants and the CFDA, as well as the facility to freely submit additional data during 
the review process [Yan et al., (2013), p.720]. 
The categories of drugs admitted to this special channel are: 
1 new drugs involving active ingredients extracted from plants, animals or minerals, 
not yet marketed in China 
2 chemical drugs, active pharmaceutical ingredients (APIs) or biological products that 
have not yet been approved in China or overseas 
3 new drugs for the treatment of AIDS, cancer, and rare or orphan diseases 
4 new drugs for the treatment of diseases without effective available therapy. 
Such categories have been expanded recently, as noted below. 
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2.1 Drug development strategies: emerging trends for speeding up new drugs 
registration 
Given this regulatory framework, Western companies have developed various strategies 
to bring their new drugs to China.13 
The most direct approach to Chinese market consists of filing an imported drug 
application. In this case, as said above, the pharmaceutical shall be in possession of the 
drug marketing authorisation (demonstrated by the Certificate of Pharmaceutical Product, 
CPP) in the producing country where the overseas pharmaceutical manufacturer is 
located. However, drugs as yet without marketing authorisation may still be approved for 
importation if applicants can confirm their safety and efficacy through clinical trials. For 
chemical drugs, it is usually necessary that the drug has been in Phase II of the clinical 
trials conducted overseas. In this case, an entire local clinical trials program (in case of 
new chemical drugs, from Phase I to Phase III inclusive) is mandatory for progress to the 
imported drugs licensing stage. “This is an aggressive scenario for imported drugs not 
marketed anywhere in the world” [Zhang, (2011), p.167]. 
Conversely, in the case of imported drugs with a CPP, the imported drug application 
approach has a high probability of success, since the drug has already been approved 
abroad and its entire dossier can be submitted to the CFDA. Furthermore, “the new drug 
has been used in a fairly big study population overseas and had passed the high-risk stage 
of the early years” [Lu et al., (2015), p.517]. Moreover, “the imported drug registration 
study can be a miniature of the Pivotal Phase III trials and simply mimic the pivotal 
Phase III trials conducted overseas with a limited scope only in China. Therefore, the 
investment is relatively small” [Lu et al., (2015), p.517]. 
However, the other side of the coin is that there is a time lag of approximatively  
five years between the initial approval overseas and the granting of Chinese approval. 
An alternative strategy for overcoming such a limitation is the local developed 
strategy, i.e., the submission of a domestic new drug application. Obviously, in order to 
do this it is necessary that foreign companies have an established local manufacturing 
structure. 
This strategy offers potential for the early launch of a drug in China, since it could be 
initiated before obtaining drug marketing approval overseas. Furthermore, the more 
extensive data collected during the local clinical trials (which is wider-ranging than in the 
aforementioned approach) and the correlated experience gained with the drug could 
become a competitive advantage in the market place [Su, (2013), p.21]. 
Moreover, there are advantages in term of exclusivity. New drugs approved under this 
scheme are entitled to a ‘monitor period’ of up to five years from the date of marketing 
approval. During this period, the CFDA will not approve any manufacturing or import 
applications for the same drug or other formulations of the drug [Su, (2013), p.21]. 
Furthermore, new drugs with new chemical entities receive six years of data protection 
(see Regulations, art. 35). “Within this period, the CFDA will reject any application made 
by other applicants using undisclosed data of the approved drug without the original 
developer’s permission, unless the follow-on applicant generated the data independently” 
[PPD, (2013), p.7]. Finally, new drug applications that meet certain requirements can 
have access to the Green channel. 
However, there are also downsides, such as the significant manufacturing investment 
and the complexity of managing a local manufacturing project [Su, (2013), p.21]. 
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In order to solve these issues or at least to mitigate them, many major multinational 
pharmaceutical companies are arranging partnerships with Chinese domestic companies 
or contract research organisations (CROs) in order to collaborate on the local 
development of innovative pharmaceuticals (Spigarelli and Wei, 2014). These 
partnerships may take different forms: licensing deals, co-development/co-promotion 
relationships or even joint ventures [Su, (2013), p.21; Deloitte, 2015].14 This 
‘collaborative’ approach, which presents challenging aspects but also substantial 
benefits,15 is also expanding to take advantage of an emerging new drug development 
strategy. 
In the past few years, another approach to the Chinese market has become more 
attractive for overseas companies wishing to accelerate new product registration: 
integration of Chinese clinical studies into MRCT. This pathway allows overseas 
companies to add China to their global development program for market approval, thus 
synchronising global market approval. 
This approach is increasingly adopted by both overseas pharmaceutical companies 
with local manufacturing structures, applying for a new drug application, and by overseas 
pharmaceutical firms without manufacturing structures applying for an imported drug 
application. In both cases this strategy has several advantages in terms of speeding up the 
registration. 
More specifically, in the case of an imported drug application supported by MRCT 
data, “since this path allows the clinical programme to start earlier and before the 
overseas market approval, submission of the NDA to the CFDA for approval could take 
place right after the overseas approval. An estimated timeframe reduction in China is 
roughly 1.5 years” [Lu et al., (2015), p.517]. 
For new drug applications, “one of the commonly accepted strategies is to initiate the 
clinical activities in China early, adopting the Class I category drug development 
strategy. Using this method, they can catch up with the western world global 
development speed. The success of this path could give global companies very early 
entry to the Chinese market compared to the traditional import drug pathway or the 
aforementioned IMCT pathways being implemented by multinational pharmaceutical 
companies without local manufacturing capabilities” [Lu et al., (2015), p.517]. 
For both applications, it is possible to take advantage of the Green Channel. This 
possibility may reduce the operational risk linked to this drug development model: in 
fact, the long CTA approval time established for the other registration channels may be 
an obstacle for China to join the global trials in time [Su, (2013), p.21]. 
Since there has been an increase in the number of recently registered MRCTs that 
integrate Chinese studies, the CFDA has issued appropriate official guidance (Guidance 
on Multi-Regional Clinical Trials, effective since 1 March 2015). The Guidance was 
preceded by several CFDA decisions resulting in regulatory delays or rejections of 
clinical trial applications for MRCT (CIRS, 2015), thus triggering alarm among foreign 
companies. Even if there is a strong interest in improving the participation of China in 
MRCT, there are accompanying concerns that the rush to MRCT for shorter approval 
could increase risks for patients, by omitting to consider potential differences in ethnicity. 
On the one hand, this document promotes MRCT for developing drugs for unmet medical 
needs and for serious life-threatening diseases; on the other, it provides new substantive 
procedural requirements for the design and implementation of an MRCT. 
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2.2 The recent drug registration reform 
The issue of the Guidance on MRCT is part of a broader reform of the registration 
process begun in 2015 and officially announced in August by the State Council with its 
circular Opinions concerning the Reform of the Review and Approval System for Drugs 
and Medical Devices (Notice [2015] No. 44, 9 August), which is being implemented 
gradually by the CFDA. One of the most relevant CFDA implementation acts is the 
Announcement on Several Policies Pertaining to the Review and Approval of Drug 
Registration ([2015] No. 230, 11 November). 
The main topics addressed by the reform include: 
• Simplifying and improving the drug registration process: 
a Eliminating the drug application backlog by 2016 thanks to more professional 
staff and financial resources for CFDA review and approval activities. 
b Simplifying approval process for clinical trials by the adoption of a one-time 
umbrella approval procedure for new drug clinical trials applications instead of a 
phase-by-phase approval, and by the introduction of a record-filing system 
instead of the review and approval system for bioequivalence studies on 
generics. 
c Self-review and voluntarily withdrawal of applications by the applicants, 
inspection of clinical data by the CFDA and severe punishment for frauds in 
clinical data. 
d Improving clinical trials permitting the conduct of parallel clinical trials in 
China for new drugs never marketed overseas and the use of data obtained from 
MRCT involving Chinese institutions in their applications. 
e Expanding the Green Channel to include more types of drug such as: paediatric 
and geriatric drugs; drugs sponsored by national science and technology grants; 
foreign innovative drugs that will be manufactured in China; drugs with 
advanced technology, innovative treatment approaches, significant therapeutic 
advantages and that are urgently needed; drugs manufactured at a US or EU 
qualified facility and under review by US FDA or EMA for concurrent 
marketing authorisation; clinical trials applications for drugs under urgent 
clinical needs and whose originator’s patent is due to expire in three years; and 
production applications for drugs whose originator’s patent is due to expire in 
one year. 
• Redefining the classification of new drugs and generics: New definition for new 
drugs, that are defined as drugs not yet been marketed worldwide and divided into 
sub-categories, innovative drugs and improved new drugs; and a new definition for 
generic drugs, i.e., drugs (already marketed either in the domestic market or 
overseas) whose quality and efficacy is equivalent to the originators’ drug. 
• Launching the Market Authorization Holder (MAH) pilot program for drugs: 
Currently, only drug manufacturers are qualified to obtain regulatory approvals. A 
MAH pilot program to be carried out in ten provinces will allow both domestic 
research and development (R&D) institutions and scientific research personnel of 
Chinese nationality to apply for approvals for new drugs and completely outsource 
production to manufacturing organisations. 
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Undoubtedly, the ongoing reform will significantly impact the Chinese healthcare market 
and have profound implications for foreign companies, that should be prepared to 
redesign their strategies to seize the opportunity provided by the new regulatory 
framework. 
3 The drugs distribution 
Planning a business in China’s pharmaceutical industry – which could mean playing in 
the manufacturing and/or distribution industry – could be extremely problematic due to a 
multi-layered structure chain and a fragmented and complex regulatory legal framework. 
3.1 Evolution and development of the distribution sector from the ‘50s to 
present 
The China’s pharmaceutical distribution system has experienced significant changes over 
the years, experiencing three stages of development: 
3.1.1 The planned economy period, from 1950 to 1979 
When the China’s pharmaceutical distribution was established for the first time, it was a 
State controlled allocation system. In this period all aspects related to pharmaceuticals 
(from production to pricing, R&D, and distribution) were centrally controlled by Chinese 
Government. The allocation of all pharmaceutical products passed mainly through three 
stages: the medical and pharmaceutical purchase and supply station, under the direct 
supervision of the central government; the wholesale station, supervised by provincial or 
municipal authorities; and wholesalers which were managed by local governments. In 
any case the structure of organisations was state-owned (Tang, 2009). 
3.1.2 The reform and open period, from 1980 to 1989 
In 1979, Deng Xiaoping launched the open door policy beginning an important era of 
economic changes for China. These were justified, regarding the pharmaceutical sphere 
as well as other economic sectors, by an essential lack of competition derived from the 
previous closed-market. The great economic transformation of this period also affected 
the distribution of pharmaceuticals, and marketisation was the primary goal for China in 
those years. For the pharmaceutical distribution sector this meant passing from a planned, 
closed and introverted economy to a market-oriented system characterised by an opposed 
decentralised structure, which progressively abandoned the three-stage organisation of 
the previous years. This left distributors and manufacturers the freedom to determine 
their preferred channels, after years with the State as the sole actors on the stage, having 
the full control of the market. 
3.1.3 The market-oriented period, from 1990 to present 
The opening up of policy caused several imported drugs, foreign investment, and 
privatisation in the Chinese market, embraced by Chinese Government since the early 
Reform and Open Period and even more evident during ‘90s, in which many 
   
 
   
   
 
   
   
 
   
   138 P. Lattanzi et al.    
 
    
 
 
   
   
 
   
   
 
   
       
 
pharmaceutical state-owned companies transformed into private or collective ownership 
companies. 
In this sense, you can say the key turning point was the Guidance on Reform of the 
Medical Distribution System,16 released in November 1999 by the former State Economic 
and Trade Commission.17 
Although the openness and marketisation should have pushed foreign investors 
toward the Chinese pharmaceutical market, we have to observe that the current market 
panorama is characterised mainly by local companies that work on a small scale with a 
low level of service. 
Being rigorous, the current Chinese distribution system could not be considered 
particularly efficient and this is due to intrinsic high costs in the distribution chain, and to 
a price-set-logic based on a tendering system. 
From the manufacturing point of view, if you compare local Chinese manufacturers 
with overseas’ standards, you will notice a more developed technical advancement in the 
latter, at all levels. 
Local manufacturers suffer the weakness of their technology and this is confirmed by 
the fact that the Chinese pharmaceutical market is completely dominated by the 
production of generic drugs;18 in other words those no longer covered by patent (see 
Figure 2). 
Figure 2 China’s pharmaceuticals market 
 
Source: Leung et al. (2014) 
For this reason 
1 very few players (principally local players) are emerging in the market and creating 
high competition 
2 companies tend more often to integrate their ab origine main business, with other 
business activities, becoming big multinational holdings and developing 
pharmaceutical distribution chains on the side, often under the direct control of the 
State. 
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This was the experience, for example, of Sinopharm which can be consider the largest 
(see Figure 3) Chinese medical and healthcare group managed by the State, with the most 
complete industrial chain coverage including distribution, retail, import-export, scientific 
research and manufacture of healthcare-related products (from medicine and medical 
devices to TCM). 
Figure 3 China wholesale and distribution market shares (%) 2014 
 
Source: Visiongain (2015) 
By analysing the Chinese pharmaceutical market by licensing status, it can be seen that 
the branded off-patented pharmaceuticals are destined to become generic pharmaceuticals 
soon after, making the Chinese generic pharmaceutical market segment even more 
enormous and, thus, even more attractive for investors – both domestic and overseas. 
This is true both for pharmaceutical manufacturing and the distribution sector, very often 
part of the same business reality. 
For this reason, representing the backbone of China’s pharmaceutical market, the 
generic sector should be taken into serious consideration. If the loss of a patent represents 
on one hand a turning down moment in one market (for example, from the US or 
Japanese pharmaceutical market), on the other hand it could represent an opportunity to 
enter the Chinese market through M&A operations with Chinese generic pharmaceuticals 
companies, to compensate their loss of income from the expired patent. This is no 
different to what happened in recent years between Simcere Pharmaceutical Company 
(better known as xiān shēng yàoyè – 先声药业) and Merck & Co. in 2012.19 
Considering this point, it should be noted that the Chinese legal term for generic drug 
is – not by chance – 仿制药 fǎngzhìyào which literally means ‘copied’ or ‘imitated’ 
drugs. 
Analysing actual possibilities, with specific respect to the pharmaceutical distribution 
industry, is to be remembered that joining by the WTO protocol (in 2001), China 
committed to gradually eliminate all limitations on market access for foreign investors. 
Before that moment China placed several restrictions on foreign investments,20 both in 
the wholesale and retail sectors. 
The 2004 version of the Foreign Investment Guidance Catalogue21 (the Catalogue) 
classified wholesale and retail activities of pharmaceutical products under the restricted 
foreign investment industries. 
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From the juridical point of view, things started to change in 2004 with the 
promulgation of the Administrative Measures for Foreign Investment in Commercial 
Sectors (briefly Measures, released by the Ministry of Commerce) in further lowering 
Chinese market barriers22 to foreigners, especially in those sectors where it was 
previously banned or limited. 
Practically, the complete actualisation of all commitments signed by China with the 
WTO, then confirmed through those Measures, with reference to the pharmaceutical 
distribution industry, occurred only in 2015 when the Catalogue was revised and both 
wholesale and retail activities were removed from the restricted category, being this way 
elevated to permitted activities. 
Nevertheless, up to 2015, investments in the wholesale and retail of pharmaceuticals 
products industries were possible, but only limited in joint venture with a Chinese 
partnership. 
Any wholly foreign-owned investment was not permitted.23 
Regarding pharmaceutical manufacturing (intended as a strategic pre-phase of a more 
structured business up to distribution), one can observe the situation over the years was 
less rigid, indeed, it has been considered by the Catalogue mostly as an encouraged 
activity.24 
In any case, as distributor or manufacturer, the generic drug sector remains the most 
attractive for foreign investor. 
The following data (see Figure 4), suggests another important piece of information: 
the target sectors (for sales) that foreign investors should aim for are both the  
over-the-counter (OTC) and prescription drugs sectors. 
Figure 4 China’s pharmaceuticals market sectors 
 
Source: Information Explorer Ltd. (2009) 
In this way, comparing results (Figure 2 and Figure 4) it can be said that OTC and 
prescription drugs (both domestic and imported ones) – which could at the same time be 
defined as generic drugs, under the Drug Administration Law of People’s Republic of 
China – have a high chance of success in the Chinese pharmaceutical market. 
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3.2 Cross border sales, wholesale and retail, manufacturing as China’s 
pharmaceutical sector challenge 
There are three main ways to enter the Chinese pharmaceutical market: cross border 
sales, wholesale and retail, and manufacturing. The choice between these three possible 
options strictly depends on the company structure (also in terms of patent and branded 
off-patent products expertise) and, even more importantly, on the investment capability 
of the company. 
Foreign investors generally opt for one of the latter two ways, as seen through M&A 
operations or, in some cases, joint venture contracts which could both be considered as 
the best emerging models for smart growth. 
• Cross border sales: Also known as country-to-country sales, can not be properly 
classified as an investment model. From a juridical point of view, sellers (from 
outside China) and buyers (based in China) engaging in cross-border-sales activities 
are doing nothing different from an import-export activity. With reference to 
pharmaceutical products, cross-border sales are permitted, but there are no special 
laws or regulations – with the exception of those regarding the import of goods into 
China (in this case medicines) such as the Administrative Measures for the Import of 
Drugs (2012) and the Notice of the State Food and Drug Administration on the 
Issues concerning the Implementation of the Administrative Measures for the Import 
of Drugs (2003,25 briefly the Notice). 
As stated in Article I of the Notice, imported drugs are allowed to enter China only 
through 18 port cities, namely, Beijing, Tianjin, Shanghai, Dalian, Qingdao, 
Chengdu, Wuhan, Chongqing, Xiamen, Nanjing, Hangzhou, Ningbo, Fuzhou, 
Guangzhou, Shenzhen, Zhuhai, Haikou, and Xi’an. 
On the foreign investors side, is not necessary to set up any foreign direct enterprise 
in China, because each part of the business relationship remains in its own home 
country. Therefore, potential trading issues are limited to administrative aspects such 
as, for example, port customs. However, do not forget the mandatory special licences 
required before importing pharmaceutical products into China, as well as drug 
registration steps (analysed above) (see paragraph 2), and quality analysis tests. 
• Wholesales and retails: domestic distribution activity is ruled by a complex legal 
framework composed by the Drug Administration Law (as amended in 2015), the 
Regulations for the implementation of Drug Administration Law (2002), the 
Measures for the Administration of Pharmaceutical Trade License (2004), Measures 
for the Supervision and Administration of Circulation of Pharmaceuticals (2007) and 
the Good supply practice for pharmaceutical products (2015). Moreover, if the 
distribution activity is carried out by a foreign investor, you have to take into further 
consideration the special legal framework provided for foreign direct investments. In 
this case the reference is to joint venture laws (both Equity and Cooperative), the 
Wholly Foreign-Owned Enterprise law and the Catalogue (last version issued  
in 2015). 
First of all, in setting up a new supply company (either wholesale or a retail), the 
enterprise itself must comply with requirements stated by the Drug Law. In other 
words: 
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1 it shall demonstrate itself to be staffed with legally certified pharmaceutical 
technical personnel 
2 it shall have business premises, equipment, storage facilities and a sanitary 
environment suitable for the pharmaceuticals in which it trades 
3 it shall have a quality control unit or personnel 
4 it shall have rules and regulations to ensure the quality of the pharmaceuticals 
(Article 15 of the Drug Law). 
If all pre-conditions for the establishment are fulfilled, the investor can apply for the 
Trade Licence from the department of Food and Drug Administration at the 
appropriate level (depending on the activity26 and where the enterprise to be 
established is located) submitting documents required by Article 8 of the Measures 
for the Administration of Pharmaceutical Trade Licence. 
The appropriate local authorities observed the fulfilment of requirements for the 
regular setting up, and checked documentation to decide whether to issue a Trade 
Licence or not (Article 14 of the Drug Law). 
This is a mandatory step, in fact, Drug Law prohibits any trade distributor from 
engaging in the pharmaceutical distribution industry without a Trade Licence. The 
Trade Licence contains important information such as the scope of trade and its 
period of validity, renewable upon the deadline. 
Moreover, all pharmaceutical distributors are required to establish a comprehensive 
quality control system. For this reason they must guarantee that all pharmaceutical 
products (to be distributed) meet Standards for Quality Control of Pharmaceutical 
Trading in conformity with the Good supply practice for pharmaceutical products27 
(briefly the GSP). 
As a proof, the legal framework on pharmaceutical distribution provides a ‘licensing 
system’ for all drugs to be distributed. As seen in the event of cross-border sales, 
even in wholesale and retail activities, drugs to be distributed must be previously 
registered.28 Moreover, the distributor must have received a valid, aforesaid, drug 
Trade Licence and, last but not least, the distributor must have GSP certification. 
Generally, the distribution of pharmaceuticals could be divided in two macro 
categories: 
1 prescription drug distribution 
2 non-prescription drug distribution (or OTC distribution) further divided into 
OTCTypeA29 and OTC-TypeB. 
The Trade Licence reports the list of drugs that distributors can trade. Contrary to 
wholesalers, retailers can sells medicines straight to patients, for this reason the 
Chinese system provides a larger protection (Article 15 of the Regulations). Retailers 
can sell prescription drug to consumers only if 
1 the consumer present a written prescription issued by a licensed physician or 
other pharmaceutical technicians whose qualifications are legally recognised 
2 the drug falls within the category of drugs that can be distributed in the light of 
the Trade Licence 
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3 the pharmacist shall review, sign and keep the prescription of the drug. 
OTC drugs are usually sold by retailers entitled by a pertinent Trade Licence, which 
reports the list of non-prescription drugs the retailer sells. 
If the investor in a distribution activity is foreigner a larger legal framework has to be 
considered, in addition to the basic regulations. Moreover, the Trade Licence shall be 
deemed as an integrative licence beyond the ordinary Business Licence (released 
form SAIC or AIC) allowing legitimate investors to legally operate in China. 
• Manufacturing: Even if the planning a business in the pharmaceutical distribution 
sector did not mean necessarily passing through a manufacturing structure,  
case-histories suggests manufacture and distribution activities are often part of the 
same project structure of many enterprises, both local and foreign. 
For an analysis example, recall the Sinopharm and the Sincere-Merck & Co 
experiences. On one hand, a local investor (Sinopharm) started as a distributor then 
integrated its industrial chain with other activities including pharmaceutical 
manufacture. And on the other hand, a sino foreign joint venture between a pure 
distributor of pharmaceutical products later became a leading manufacturer and 
supplier of drugs in China (Simcere) and a multinational leader (Merck & Co) in full 
phase of expansion in the Chinese market. 
In both experiences distribution business activities were in someways linked with 
the manufacturing activity. 
Actually this is not particularly strange, considering the features of the Chinese 
pharmaceuticals market. As already seen, it is characterised by sectors, by the 
predominance of the OTC and generic-drugs sales which make completion higher, 
by market shares, and by the overall control of Chinese enterprises, often  
state-owned or state-participated which leaves a poor business environment. 
The multi-layered system of distribution, then, is not helpful and, for locals, the 
inadequate advancement in technologies has increased the need to improve skills and 
expertise, which only foreign R&D enterprise can contribute and compensate. 
It is not by chance that the current situation describes (Wang and Zedtwitz, 2005) a 
predominance of foreign companies in R&D rather then in distribution or 
manufacture. 
In many cases the local presence in China begins with R&D collaborations (as 
happened in joint venture between Simcere and Merck & Co) which can represent at 
the same time a larger sales platform for the foreign part, and a broader collaboration 
in research addressed to technology advancement for the Chinese one. 
As well as for wholesales and retail activities, Chinese legislation also provides a 
licence system for manufacturing activities, a part from the Trade Licence eventually 
released for an ‘extensive’ distribution activity. 
To start a manufacturing business, both domestic and foreign, the company needs to 
apply for a manufacturing licence. Generally, the licence includes the ‘green-light’ 
for distribution, but limited to drugs the manufacturer have produced. For the 
distribution of an ‘extensive’ list of drugs (produced elsewhere) the investor must 
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obtain a Trade Licence. The legal framework mainly refers to the Drug Law, to the 
Regulations, and the Good Manufacturing Practice for Pharmaceutical Products 
(2011). Also, if the activity in this sector is carried out by foreigners this – basic – 
legal framework shall be integrated by the special provisions reserved for overseas 
investors. 
3.3 Models and multi-layered structure of China’s distribution industry 
M&A operations and joint ventures currently represent preferred ways to enter the 
Chinese pharmaceutical sectors. Besides the weakness of Chinese companies and their 
considerable generic drug-market market share, reasons which further make M&A and 
joint ventures the main channel of entrance in China’s pharmaceutical distribution 
segment are found in its multi-layered complex structure. 
Most drug manufactures are not allowed to sell pharmaceuticals directly to retailers 
(hospitals and pharmacies). Generally, they must go through state-owned wholesalers. 
For this reason, it is quite obvious, thus, being a local manufacturer or simply being in 
China (through a sino-foreign joint venture or a M&A operation) could mean being 
favoured in the complex distribution context. 
To better understand, it is worth noting Chinese hospitals have been traditionally the 
principal distributors of drugs to patients and this practice finds its origin in the country’s 
economic development. 
During the Deng Xiaoping Era (from 1979 onwards) China launched its economic 
reform aimed at boosting its economic growth; the organisation and the management of 
the Chinese healthcare framework changed radically, to fall in line with most other 
Chinese economic sectors. 
With the policy shift towards the introduction of the market economy in the early 
1980s, state-owned enterprises could no longer meet the financial costs of social security. 
All medical institutions of all types and levels were made responsible for their own 
well-being with the consequence of a renewed profit-seeking healthcare system, often too 
expensive for patients (especially those in rural areas, where insurance programs were 
weak). 
The commonly heard phrase among people 看病难，看病贵 (kànbìng nán, kànbìng 
guì, which means “seeing a doctor is hard and expensive”) clearly summarises the 
healthcare situation in that period. An interesting study (Meng et al., 2004) conducted in 
2004 demonstrates that awareness of this phenomenon is common among the people, 
whose frequent complaints (about public doctors in public medical structures) concern 
over-prescription cases. People (in that study mainly coming from Guangdong, Shanxi 
and Sichuan provinces) said: “The [public] doctor prescribes more drugs for you because 
their bonus is related to the volume of the drugs they prescribe”. 
This explains clearly two important things: first of all why hospitals have historically 
been the main way of retailing of drugs in China (they were traditionally public), and 
second why over the years patients started to fear hospital services (they tend to  
over-prescript drugs). 
Just think in 1980, in the early economic opening phase, Chinese hospitals already 
accounted for about 95% of all drug sales (Pharma Handbook, 2007) and in 2003 the 
percentage of hospitals sales increased approximately at 85% (Von der Hagen et al., 
2002). 
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Although things seem to change (Wang, 2015), the current situation demonstrates that 
hospital reliance on drugs is still very high (see Figure 5). 
Figure 5 Hospital revenue composites in 2011 
 
Source: Citi Research (2012) 
Sales from hospitals or pharmacies to patients are only the he last link in the chain. 
As already underlined, the Chinese distribution chain is extremely complex and it is 
characterised by a hierarchical multi-layered structure at a national, regional and local 
level. In many cases, before drugs arrive at hospitals and/or pharmacies, it takes three, 
four or even more steps through a long chain of intermediaries and sub-distributors which 
increase prices. 
Returning to the above point, having a physical presence in China could help foreign 
investors to success in the market. 
Remember that hospitals purchase most of their pharmaceutical products through a 
price-set-logic based on a tendering system and, even with poorer quality products, local 
companies are more favoured in this distribution-chain step. 
The tendering system was originally developed, by the Chinese Government, as a 
pilot project between 2001 and 2002, then extended nationally to contain drugs’ costs, 
quickly becoming a price-competition moment between manufacturers. 
The bidding price, determined as the ‘winner price’, represents the starting point for 
hospitals (or other medical institutions) to determine the final price (for the patient, often 
for medicines not covered by the social insurance scheme and for this reason not 
reimbursed) with higher profit margin possibilities. 
Once or twice per year each province issues a call for proposals, so running for a 
specific province call does not guarantee approval in another province. 
After the call, all local and foreign manufacturers are invited to submit offers and, 
after a qualification inspection, provinces or administrations which launched the call, 
decide whether to admit the bid or not. Once the prices are determined they will be 
reported to the local bureau of the Ministry of Health for the public announcement of the 
bid winners. 
Because of the country size, even distributors30 who are professional and well-funded 
are not able to operate in all regions of China or toward to all hospital’s typologies. 
Therefore foreign companies tend to establish more relationships with multiple 
distributors to guarantee themselves a wider distribution across China. 
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4 Pharmaceutical innovations and IP rights 
Intellectual property rights (IPRs) are the key elements in the promotion of 
pharmaceutical innovations. Among all types of IPRs, the most important bases for the 
commercial business models of pharmaceutical industry are patents, trademarks and trade 
secrets. In the last 30 years, China has established a comprehensive IP system on the 
protection of pharmaceutical products. 
4.1 Patent 
The revisions of Chinese Patent Law are mostly accompanied with the change of the 
rules on pharmaceutical patents. In the first version of Chinese Patent Law enacted on 
April 1, 1985, article 25 stated that “patent will not be provided for drug or new chemical 
entity.” In the next version revised on January 1, 1993, the scope of patent protection 
extended to include drug and new chemical entity and products, mainly to keep it 
consistent with the TRIPS. Revisions in 2000 confirmed the 1993 patent law, clearly 
providing all drugs in China with patent protection. In the last revision in 2008, Bolar 
exemption was officially introduced into the Patent Law (Yin, 2012). 
Nowadays in China, if pharmaceutical products could meet the patentability standards 
set out in the patent law, patent rights should be granted. Pharmaceutical product related 
invention is equally treated with the invention in other fields during patent examination. 
It has to meet the requirements, such as novelty, non-obviousness, capable of industrial 
application, sufficient disclosure, provided in the Guidelines for Patent Examination. 
In the meantime, to balance the relationship between IPRs, R&D incentives, pricing 
and access to medicines, some regulations that are specific to the pharmaceutical sector, 
such as Bolar exemption, public health related compulsory licensing, were established in 
Chinese Patent Law. 
Bolar exemption, named after the US case Roche Products v. Bolar Pharmaceutical, 
permits generic manufactures exempted from infringement for certain acts relating to the 
development and submission of testing data to a regulatory agency. 
Article 69 (5) of the current Patent Law stipulates that “None of the following shall 
be deemed an infringement of the patent right: (5) where for the purposes of providing 
information needed for the regulatory examination and approval, any person makes, uses 
or imports a patented medicine or a patented medical apparatus, and where any person 
makes, imports the patented medicine or the patented medical apparatus exclusively for 
such person.” 
According to this provision, not only the generic manufacture and R&D organisation, 
but also the third party manufacturer could be exempted from infringement of patented 
rights. Medical apparatus also forms part of the exempted subject-matter. 
Compulsory licensing is the method a country can use to circumvent the traditional 
process of requesting permission to use patented material [Lewis, (2014), p.1056]. 
“China has never granted any compulsory licence, nor does it seem likely that it will in 
the near future. But on February 3, 2010, at a State Intellectual Property Office (SIPO) 
press conference regarding the announcement of the new Implementing Regulations for 
the Patent Law, a SIPO spokesperson stated that, if China were to begin granting 
compulsory licence, it would likely start with pharmaceutical patents relating to public 
health” (Ma, 2011). 
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The basic compulsory licensing mechanism has existed in the Patent Law for over a 
decade. Chapter VI of the Patent Law provides that a compulsory licence may be 
awarded by SIPO when an applicant can establish one of the following circumstances: 
1 a patentee has failed to exploit a patent without reasonable justification for more than 
three years from the date of grant and four years of the date of filing (Article 48.1) 
2 a patentee’s patent use is determined to be monopolistic and a compulsory licence 
would remove or reduce the anticompetitive effects of such patent use (article 48.2) 
3 public interest, extraordinary circumstances, or national emergency requires a 
compulsory licence (Article 49) 
4 public health interests require that a compulsory licence on patented medicine is 
granted to export the medicine to underdeveloped countries when such countries 
conform to the provisions of relevant international treaties (Article 50) 
5 major technical improvements with significant economic impact are dependent on 
earlier patents (Article 51). 
Except for the Patent Law, SIPO promulgated Measures for Compulsory Licensing of 
Patent Implementation in 2003, and Measures for Compulsory License on Patent 
Implementation Concerning Public Health Problems in 2005. There two provisions were 
abolished, and replaced by Measures for the Compulsory Licensing for Patent 
Implementation (hereinafter the 2012 Measures), which came to effect on May 1, 2012. 
The 2012 Measures provide more detailed and better defined procedures for examining 
and terminating compulsory licences under applicable patent laws. 
It has to be emphasised that, supplementary protection certificate (SPC), which is 
introduced as a means to extend the patent term of protection for medicinal products to 
compensate brand name manufactures for the time period required to obtain regulatory 
approval, does not exist in Chinese Patent Law [Tang, (2005), p.45]. 
However, six years of data exclusivity,31 a SPC alike non-patent related right, which 
is also serves the purpose of encouraging the development of new medicines, is provided 
by Regulations for Implementation of the Drug Administration Law, and Provisions for 
Drug Registration in China. 
4.2 Trademark 
In China, pharmaceutical trademarks are governed by Trademark Law and Drug Law. 
Both Trademark Law and Drug Law seek to prevent potential confusion in the relevant 
business circles due to similarities between conflicting trademarks. There are three types 
of names associated with drugs: trademark, generic name and drug product name. 
The use of registered trademark is a compulsory requirement to put the drug into the 
market. Article 27 of the Provisions on the Administration of Drug Directions and Labels 
provides that it is prohibited to use any unregistered trademark or any other 
pharmaceutical name not approved by the CFDA on drug directions and labels. Article 6 
of the Trademark Law stipulates “with respect to the commodities that the state has 
designated as requiring the use of a registered trademark, an application for trademark 
registration must be filed; the commodities may not be sold on the market before the 
registration is granted.” 
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A generic name is a standard legal name generated by Chinese Pharmacopoeia 
Commission for a pharmaceutical product using the same active ingredient or formula in 
China, which is officially called China Approved Drug Name (CADN). It is usually the 
transliteration of an International Non-proprietary Name (INN) generated by the WHO 
for the product. The generic name of drugs shall not be applied as a trademark. 
A drug product name is generated by drug producer itself, mostly for originators’ 
drugs, but has to be approved by CFDA. Now, the CFDA will not approve an originator’s 
use of a specific drug product name unless the product name is registered as a trademark 
(He et al., 2015). 
4.3 Trade secret 
China’s rules defining and regulating trade secrets are scattered among a series of laws 
and regulations. In 1985–2002, over 130 trade secret related laws and regulations were 
issued, and the most important of these is the Anti-Unfair Competition Law (AUCL), 
which was released in 1993 [Shan, (2004), p.81]. 
AUCL defines trade secret as “any technology information or business operation 
information which is unknown to the public, can bring about economic benefits to the 
oblige, has practical utility and about which the obligee has adopted secret-keeping 
measures.” 
The following actions are taken as infringement of trade secret under AUCL: 
1 obtaining an obligee’s trade secrets by stealing, luring, intimidation or any other 
unfair means 
2 disclosing, using or allowing another person to use the trade secrets obtained from 
the obligee by the means mentioned in the preceding paragraph 
3 in violation of the agreement or against the obligee’s demand for keeping trade 
secrets, disclosing, using or allowing another person to use the trade secrets he 
possesses. 
Moreover, obtaining, using or disclosing another’s trade secrets by a third party who 
clearly knows or ought to know that the case falls under the unlawful acts listed in the 
preceding paragraph shall be deemed as infringement upon trade secrets. 
Additional aspects of trade secret protection and management are covered in other 
laws and regulations, including Article 43 of the Contract Law,32 Article 62 of the 
Company Law,33 Article 22 of the Labor Law,34 Article 23 of the Labor Contract Law35 
and Article 219 of the Criminal Law36. 
5 Concluding remarks 
Investing in the pharmaceutical sector still remains very challenging because of the 
fragmented structure of the healthcare management overall and, with reference to 
pharmaceutical distribution chain, due to the multilayered structure. 
The comprehension of the China’s pharmaceutical market, in fact, can not exclude the 
analysis and the deep consideration of socio-economical factors (for instance, the 
population ageing, the increase of new diseases) and the ongoing juridical edification of 
the Chinese pharmaceutical legal framework. 
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Up to date China, indeed, has been strengthening its pharmaceutical legislation 
toward a better and more comprehensive healthcare environment. From the perspective of 
foreign companies, the interest in refining legislation represents a positive trend towards 
the removal of legal and regulatory hurdles affecting their business. However, this 
process of ‘never-ending changes’ tends to generate legislative instability and lack of 
legal certainty. Thus, foreign investors have been forced to continuously update their 
knowledge of the complex and fast-changing Chinese pharmaceutical legal landscape, 
and their ability to “develop sound regulatory strategies and navigate the Chinese 
regulatory system” has become one of the most “important success factors” [Su, (2013), 
p.23]. 
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Notes 
1 Sub-paragraph 1.1, within the Paragraph 1 is credited to Federica Monti; 1.2 to Pamela 
Lattanzi. Paragraphs 2 and its subparagraphs are credited to Pamela Lattanzi; Paragraph 3 and 
its subparagraphs are credited to Federica Monti; Paragraphs 4 and its subparagraphs are 
credited to Zhao Xu. Conclusion is credited to Federica Monti and Pamela Lattanzi. 
2 According to the China statistical yearbook, the leading causes of death (crude mortality) in 
the last ten years, both in urban and rural areas, are respectively: malignant tumours, heart 
diseases, cerebrovascular diseases, diseases of the respiratory system, trauma and toxicosis. 
3 The term Pharmerging markets refers to those markets which have rank high-growth and 
power to conquer a global considerable market share. The industry consultancy IMS Health 
(2010) has pinpointed 17 Pharmerging Markets, among them and beside China there are 
countries such as Brazil, Russia, India, South Korea, Turkey and others. 
4 In this sense could be read the Novartis case history (Festel, Kreimeyer, Oels, Zedtwitz , 
2005). 
5 The Drug Administration Law of the People’s Republic was first published on September 20, 
1984. It was revised at the 20th Meeting of the Standing Committee of the Ninth National 
People’s Congress on February 28, 2001 and became effective on December 1, 2001. The Law 
saw a substantive update in 2015, effective as of April 24. 
6 The first comprehensive drug regulation of the People’s Republic of China was published in 
1963: Provisions for Pharmaceutical Administration, followed in 1965 by Interim Provisions 
of New Drug Administration. Both regulations were not enforced because of the Cultural 
Revolution, lasting from 1966 to 1976. In the late 1970s the State Council adopted the 
Pharmaceutical Regulation (1978) concerning clinical trials and new drug approvals, 
implemented by the New Drug Regulation (1978). Under these regulations, market 
authorisations for most new drugs were issued by provincial health departments without 
commissioning scientific experiments to prove the quality and efficacy of the drugs, with the 
result that local pharmaceutical manufacturers could easily receive approval (Yan et al., 2013; 
Zhang, 2013). 
7 The Regulations were approved by the State Council and became effective on September 
2002. 
8 According to CFDA Drug Review Annual Report 2014, more than 18,500 drugs applications 
were waiting for approval at the end of 2014. 
9 The latest version of the Provisions for Drug Regulation (SFDA Issue no. 28) was issued by 
the SFDA on 10 July 2007 and enacted on 1 October 2007. The Provisions are currently under 
review. 
10 A drug is defined as an article that is used in the prevention, treatment, or diagnosis of 
diseases in humans and that is intended for the regulation of the physiological functions of 
humans (see Drug Administration Law, article 100). 
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11 The main difference between the two procedures concerns the submission of the registration 
application, which in the case of a new drug application, must be submitted to the CFDA 
through its local counterparts (Provincial Food and Drug Administration); but for an imported 
drug, the application must instead be submitted directly to CFDA. Moreover, the procedure of 
this latter application demands that a sample of the drug be tested at the National Institute for 
the Control of Pharmaceutical and Biological Products (NICPBP) or at a test institute 
designated by the NICPBP. Finally, all documents need to be in Chinese [Yan et al., (2013), 
p.719]. Because a registration application can be carried out only by a Chinese legal entity, 
foreign manufacturers can apply for product registration through their Chinese branch or an 
entrusted agency within Chinese territory if they are without legal representation in China (see 
Provisions, article 10). 
12 MRCTs are forbidden for preventive vaccines not yet registered overseas. 
13 “For an imported generic drug, even if the CPP is available at the beginning of the CTA 
submission, the CFDA will regulate it as a generic drug application with the requirement of 
dossier, clinical trial, and timeline” [Zhang, (2011), p.164]. 
14 “Since the drugs control system of in China is based on the manufacturer’s location, the 
transfer of final product manufacture to a subsidiary or a joint venture, or to a third party in 
China means that the CTA from this entity is regarded as the first stage of a domestic NDA, 
regardless of whether the subsidiary or joint venture is 100 percent owned by a foreign 
company” [Zhang, (2011), p.167]. 
15 “A partnership approach presents unique benefits, as 18 local companies tend to be more 
efficient operationally due to familiarity with the local R&D and regulatory environment. 
They also capitalize on policy incentives that lead to shortened approval times and reduced 
development costs” [Deloitte, (2015), p.4]. However, it is notable that foreign investors must 
take into consideration the complexity of identifying and working with the partner and 
correctly managing IP issues that may arise during the development process and other legal 
and business matters [Su, (2013), p.23]. 
16 The reference is to the 关于印发《深化医药流通体制改革的指导意见》的通知 (1999) 
1055号. 
17 The former State Economic and Trade Commission (SETC) in 2003 was incorporated in the 
Ministry of Commerce. 
18 As already seen above, a rough classification of Chinese pharmaceuticals could be obtained 
reading the Article 100 of the Pharmaceutical Administration Law of People’s Republic of 
China which seems to want to classify drugs into three macro groups: Traditional Chinese 
Medicine – TMC – (such as raw TCM materials – 包括中药材 –, TMC prepared in  
ready-to-use portion – 中药饮片 – or prepared TMC – 中成药–); chemical drugs (such as 
medicinal chemicals and their preparations – 化学原料及其制剂 –, antibiotics – 抗 生素 –, 
biochemical medicines – 生化药品 –, radioactive drugs -放射性药品 –); Biological products 
(such as serum – 血清– , vaccines – 疫苗 –, blood products – 血液制品 –). A partially 
different classification is provided by the article 11 of the Provision for Pharmaceutical 
Registration which provides pharmaceutical products divided as: new drugs – 包括新药 –, 
generic drugs – 仿制药 –, import drugs – 进口药 – and their supplementaries. 
19 Merck & Co. is an US-based pharmaceutical company, among the biggest in the world. It is 
known as an international developer, manufacturer and distributor of pharmaceuticals. 
Simcere is a well-known Chinese manufacturer and distributor of generic drugs. In 2012, the 
two companies decided to set up a Joint Venture (JV) merging their expertise and resources 
(51% was left to the foreign partner and the remaining to the Chinese part). In that case, 
clauses of JV contract provided the exclusive right of the JV to sell some metabolic and 
cardiovascular drugs, before the blockbuster of the foreign company then off-patented. The JV 
permitted to Simcere to enjoy massive advantages from off-patented drugs of the Merck & Co. 
In this case Merck & Co. did not use the JV with Simcere to enter the market (Merck & Co. 
had already entered the market in 1994, in Hangzhou) but to expand its market, taking 
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advantages to its off-patented drugs. Another similar, and most recent case history, is 
represented by the JV set up by Pfizer Chinese and Zhejiang Hisun Pharma. 
20 For example, previous 2004 foreign retailers could operate only in major cities and special 
economic zones. 
21 Foreign Investment Guidance Catalogue represent a very 24 important legal reference for 
foreign investors providing a classification of business activities into three macro categories: 
encouraged, restricted and prohibited. Those not classified shall be deemed as permitted. The 
Catalogue was issued for the first time in 1997, then amended several time in 2002, 2004, 
2007, 2011 and 2015. The current version of the Catalogue can be retrieved from: 
http://www.fdi.gov.cn/1800000121_39_4830_0_7.html. 
22 In this sense, can be read Article 3 of the Administrative Measures for Foreign Investment in 
Commercial Sectors provides. 
23 Provisions provided for the distribution of general goods was quite different form those which 
provides on the distribution of drugs. For the first one the measures allowed foreign investors 
to provide retail services through out Joint Ventures or, indifferently, Wholly Foreign-Owned 
Enterprises. 
24 Under Catalogue (2007 version) manufacture industry provided: 16 types of products and 10 
types of equipments as encouraged, product such as immunity vaccines, psychotropic, blood 
products as restricted and stem cells, gene therapy as prohibited. So permissions in doing 
business in that sector were strongly linked on the nature of the drugs to be manufactured. 
Moreover with the amendment occurred in 2007 for special pharmaceutical and healthcare 
products manufacturing, industries structured as Wholly Foreign-Owned, were allowed to 
operate only on a pilot zones. Further enhancements came after the launch of the new edition 
of the Catalogue in 2015 and medical and pharmaceutical activities, previously restricted, 
became permitted. 
25 As you can see, the Notice’s date of issue is previous than the main Administrative Measures 
for the Import of Drugs, which represent the main legal reference for imported drug. This 
happened because the first version for the Measures for the Import of Drugs (then amended in 
2012) were promulgated in 2003 and entered in force in 2004. Contextually were issued also 
Notice for the proper implementation. Although the Measures for the Import of Drugs’ 
amendment previous Notice shall be still deemed as effective. 
26 For wholesale activities the competent level of the Food and Drug Administration, is the 
provincial one whereas for retail activities the municipal or county level one. 
27 Good supply practice for pharmaceutical products was issued for the first time in July 2000 
and it was implemented by the Promulgating Provisions for the Administration of Drug GSP 
Certification promulgated in 2003. The Ministry of Health, after several years of drafting and 
public consultation, had replaced the Good supply practice for pharmaceutical products on 22 
January 2013 and then further amended in 2015, strengthening even more the quality 
management of drug distribution in China. 
28 You have to remember the registration for an imported drug is not the same as for domestic 
drug (see paragraph 2). 
29 The distinction in OCT-TypeA AND OTC-TypeB 32 depends on the level of hazardousness 
(or safety) of a drug for which Government could have provided, depending of the cases, a 
flexible or a more strict regulation. For example, OTC-TypeA can be sold only by retain 
pharmacies with a in-store licensed pharmacist or pharmacy technician, whereas OTC-TypeB 
can be sold by regular business enterprises, which means, enterprise with at least one full-time 
well-skilled and trained employee, or can be sold in ordinary shops such as supermarket, 
grocery stores and so on. 
30 For example, Shanghai Pharma enjoy higher ratio of direct hospital sales, Jointown has 
nations coverage whereas Nanjing pharma is mainly a regional players. About this see more 
on Changing landscape of China’s Pharmaceutical distribution Industry, retrieved 
from:http://www.strategyand.pwc.com/media/file/Changing_Landscape_of_China’s_-
Pharmaceutical_Distribution_EN.pdf. You have to take in further consideration even not all 
distributor are at the same level, you can have in fact general distributor or special distributors 
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(for special classes of drugs), their distinction will be made on the basis of their respective 
Trade Licence. 
31 Here, the ‘data’ means safety and efficacy related information of a new medicine collected by 
a brand name manufacture through pre-clinical and clinical trials. Submission of these data, 
where the generation takes considerable time, effort, expense and economic risk, is required 
by the regulation agency to get a marketing authorisation. Data exclusivity provides limited 
period during which the generic manufacture may not refer to the data of an originator to 
apply for a marketing authorisation. 
32 Article 43 of the Contract Law stipulates that “Neither party may disclose or inappropriately 
exploit business secrets obtained in the making of a contract no matter the contract is executed 
or not. The party that disclose or inappropriately exploits the said business secrets causing thus 
loss to the other party shall hold the liability for the loss.” 
33 Article 62 of the Company Law stipulates that “Unless required by law or consented to by the 
shareholders’ committee, a director, supervisor, or the general manager may not disclose the 
company’s confidential information.” 
34 Article 22 of the Labor Law stipulates that “The parties to a labor contract may stipulate in the 
labor contract matters concerning keeping business secrets of the employing unit.” 
35 Article 23 of the Labor Contract Law stipulates that “An employing unit and a worker may 
have such terms stipulated in the labor contract as keeping business secrets of the employing 
unit and keeping confidential the matters relating to its intellectual property right. With regard 
to a worker who has a confidentiality obligation, the employing unit may stipulate in the labor 
contract or confidentiality agreement competition restriction and payment of financial 
compensation to him on a monthly basis during the term of the competition restriction after 
the labor contract is revoked or terminated. If the worker breaches the stipulation on 
competition restriction, he shall pay penalty to the employing unit as agreed upon.” 
36 Article 219 of the Criminal Law stipulates that “40 Whoever commits any of the following 
acts of infringing on business secrets and thus causes heavy losses to the obligee shall be 
sentenced to fixed-term imprisonment of not more than three years or criminal detention and 
shall also, or shall only, be fined; if the consequences are especially serious, he shall be 
sentenced to fixed-term imprisonment of not less than three years but not more than seven 
years and shall also be fined: 
(1) obtaining an obligee’s business secrets by stealing, luring, coercion or any other 
illegitimate means 
(2) disclosing, using or allowing another to use the business secrets obtained from the obligee 
by the means mentioned in the preceding paragraph; or 
(3) in violation of the agreement on or against the obligee’s demand for keeping business 
secrets, disclosing, using or allowing another person to use the business secrets he has. 
Whoever obtains, uses or discloses another’s business secrets, which he clearly knows or 
ought to know falls under the categories of the acts listed in the preceding paragraph, shall 
be deemed an offender who infringes on business secrets. ‘Business secrets’ as mentioned 
in this Article refers to technology information or business information which is unknown 
to the public, can bring about economic benefits to the obligee, is of practical use and with 
regard to which the obligee has adopted secret keeping measures. 
‘Obligee’ as mentioned in this Article refers to the owner of business secrets and the 
person who is permitted by the owner to use the business secrets.” 
